Montmorency Cherry Supplementation, Sleep, and Inflammation
Primary Purpose
Insomnia Chronic, Inflammation
Status
Not yet recruiting
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Montmorency cherry supplement
Control
Sponsored by

About this trial
This is an interventional treatment trial for Insomnia Chronic
Eligibility Criteria
Inclusion Criteria: body mass index (BMI) of ≥ 25.0 kg/m2; sleep issues as identified by a global score of 5 or greater on the Pittsburgh Sleep Quality Index (PSQI) and/or a score 8 or higher on the Insomnia Severity Index (ISI); ability to adhere to a diet low in antioxidants during the study period; and willingness to wear a Fitbit for the duration of the study and to wear the Zmachine on selected nights. Exclusion Criteria: unwilling or unable to stop the use of sleep medication unable to attend laboratory visits on the East Lansing, Michigan campus
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Intervention
Control
Arm Description
500 mg cherry supplement
Placebo
Outcomes
Primary Outcome Measures
Change in total sleep time
sleep duration in hours and minutes
Change in sleep quality
Pittsburgh Sleep Quality Index scores, scores range from 0-21, higher scores indicate worse outcomes
Change in insomnia symptoms
Insomnia Severity Index scores, scores range from 0-28, higher scores indicate worse outcomes
Secondary Outcome Measures
Change in C-reactive protein
blood work
Change in Interleukin-6
blood work
Change in Interleukin-8
blood work
Change in Interleukin-17
blood work
Change in Tumor necrosis factor-alpha
blood work
Change in Anthropometrics
Percent body fat
Full Information
NCT ID
NCT05700643
First Posted
December 7, 2022
Last Updated
January 17, 2023
Sponsor
Michigan State University
Collaborators
Cherry Marketing Institute
1. Study Identification
Unique Protocol Identification Number
NCT05700643
Brief Title
Montmorency Cherry Supplementation, Sleep, and Inflammation
Official Title
Effects of Montmorency Cherry Supplementation on Sleep and Inflammatory Outcomes
Study Type
Interventional
2. Study Status
Record Verification Date
January 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
January 18, 2023 (Anticipated)
Primary Completion Date
January 17, 2024 (Anticipated)
Study Completion Date
January 17, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Michigan State University
Collaborators
Cherry Marketing Institute
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study will test the effects of Montmorency cherry supplementation on sleep outcomes and inflammatory biomarkers.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insomnia Chronic, Inflammation
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
64 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Intervention
Arm Type
Experimental
Arm Description
500 mg cherry supplement
Arm Title
Control
Arm Type
Placebo Comparator
Arm Description
Placebo
Intervention Type
Dietary Supplement
Intervention Name(s)
Montmorency cherry supplement
Intervention Description
Montmorency cherry supplement
Intervention Type
Dietary Supplement
Intervention Name(s)
Control
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
Change in total sleep time
Description
sleep duration in hours and minutes
Time Frame
Through study completion, two weeks for each arm
Title
Change in sleep quality
Description
Pittsburgh Sleep Quality Index scores, scores range from 0-21, higher scores indicate worse outcomes
Time Frame
Through study completion, two weeks for each arm
Title
Change in insomnia symptoms
Description
Insomnia Severity Index scores, scores range from 0-28, higher scores indicate worse outcomes
Time Frame
Through study completion, two weeks for each arm
Secondary Outcome Measure Information:
Title
Change in C-reactive protein
Description
blood work
Time Frame
Through study completion, two weeks for each arm
Title
Change in Interleukin-6
Description
blood work
Time Frame
Through study completion, two weeks for each arm
Title
Change in Interleukin-8
Description
blood work
Time Frame
Through study completion, two weeks for each arm
Title
Change in Interleukin-17
Description
blood work
Time Frame
Through study completion, two weeks for each arm
Title
Change in Tumor necrosis factor-alpha
Description
blood work
Time Frame
Through study completion, two weeks for each arm
Title
Change in Anthropometrics
Description
Percent body fat
Time Frame
Through study completion, two weeks for each arm
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
body mass index (BMI) of ≥ 25.0 kg/m2;
sleep issues as identified by a global score of 5 or greater on the Pittsburgh Sleep Quality Index (PSQI) and/or a score 8 or higher on the Insomnia Severity Index (ISI);
ability to adhere to a diet low in antioxidants during the study period; and
willingness to wear a Fitbit for the duration of the study and to wear the Zmachine on selected nights.
Exclusion Criteria:
unwilling or unable to stop the use of sleep medication
unable to attend laboratory visits on the East Lansing, Michigan campus
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Robin Tucker, PhD
Phone
517-353-3408
Email
tucker98@msu.edu
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
Aggregate data available upon request upon completion of analysis.
Learn more about this trial
Montmorency Cherry Supplementation, Sleep, and Inflammation
We'll reach out to this number within 24 hrs